Alex Gorsky - Johnson Johnson Chairman of the Board, Chief Executive Officer
| JNJ Stock | EUR 147.00 0.18 0.12% |
Chairman
Mr. Alex Gorsky is Chairman of the Board, Chief Executive Officer of Directors of the Company. He was appointed as Chairman, Board of Directors in December 2012. He was named Chief Executive Officer, Chairman of the Executive Committee and joined the Board of Directors in April 2012. Mr. Gorsky began his Johnson Johnson career with Janssen Pharmaceutica Inc. in 1988. Over the next 15 years, he advanced through positions of increasing responsibility in sales, marketing, and management. In 2001, Mr. Gorsky was appointed President of Janssen Pharmaceutical Inc., and in 2003 he was named Company Group Chairman of the Johnson Johnson pharmaceutical business in Europe, the Middle East and Africa. Mr. Gorsky left Johnson Johnson in 2004 to join Novartis Pharmaceuticals Corporationrationration, where he served as head of the companys pharmaceutical business in North America. Mr. Gorsky returned to Johnson Johnson in 2008 as Company Group Chairman for Ethicon. In early 2009, he was appointed Worldwide Chairman of the Surgical Care Group and member of the Executive Committee. In September 2009, he was appointed Worldwide Chairman of the Medical Devices and Diagnostics Group. Mr. Gorsky became Vice Chairman of the Executive Committee in January 2011. Mr. Gorsky also serves on the boards of the Travis Manion Foundation, the Congressional Medal of Honor Foundation, the National Academy Foundation, and the Wharton Board of Overseers. He is also a member of the Board of Directors of the Business Roundtable and serves as the Chairman of its Corporationrationrate Governance Committee. since 2012.
| Age | 58 |
| Tenure | 12 years |
Johnson Johnson Leadership Team
Elected by the shareholders, the Johnson Johnson's board of directors comprises two types of representatives: Johnson Johnson inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Johnson. The board's role is to monitor Johnson Johnson's management team and ensure that shareholders' interests are well served. Johnson Johnson's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Johnson Johnson's outside directors are responsible for providing unbiased perspectives on the board's policies.
| A Washington, Independent Director | ||
| Jennifer Doudna, Independent Director | ||
| Alex Gorsky, Chairman of the Board, Chief Executive Officer | ||
| Michael Sneed, Executive Vice President - Global Corporate Affairs and Chief Communication Officer | ||
| Ashley McEvoy, Executive Vice President - Worldwide Chairman, Medical Devices | ||
| Marillyn Hewson, Independent Director | ||
| Ronald Williams, Independent Director | ||
| Kathryn Wengel, Executive Vice President Chief Global Supply Chain Officer | ||
| Michael Ullmann, Executive Vice President, General Counsel | ||
| Joaquin Duato, Executive Vice President Worldwide Chairman - Pharmaceuticals | ||
| D Davis, Independent Director | ||
| Hubert Joly, Independent Director | ||
| Jennifer Taubert, Executive Vice President - Worldwide Chairman, Pharmaceuticals | ||
| Anne Mulcahy, Lead Independent Director | ||
| Mary Beckerle, Independent Director | ||
| Joseph Wolk, Chief Financial Officer, Executive Vice President | ||
| Thibaut Mongon, Executive Vice President Worldwide Chairman, Consumer | ||
| Ian Davis, Independent Director | ||
| Paulus Stoffels, Chief Scientific Officer, Worldwide Chairman - Pharmaceuticals Group | ||
| Mark McClellan, Independent Director | ||
| Charles Prince, Independent Director | ||
| Peter Fasolo, Chief Human Resource Officer, Executive Vice President | ||
| Mark Weinberger, Independent Director |
Johnson Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Johnson Johnson a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Current Valuation | 443.95 B | |||
| Price To Book | 6.23 X | |||
| Price To Sales | 4.94 X | |||
| Revenue | 94.94 B | |||
| EBITDA | 28.97 B | |||
| Net Income | 17.94 B | |||
| Total Debt | 26.89 B | |||
| Cash Flow From Operations | 21.19 B | |||
| Price To Earnings To Growth | 3.83 X | |||
| Number Of Employees | 33 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Johnson Stock
When determining whether Johnson Johnson is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Johnson Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Johnson Johnson Stock. Highlighted below are key reports to facilitate an investment decision about Johnson Johnson Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Johnson Johnson. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Johnson Stock refer to our How to Trade Johnson Stock guide.You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.